Ciprofloxacin for Prevention of BK Infection

Status Completed

Clinical Trial Summary

BK infection is an important cause of graft dysfunction and graft loss after renal transplantation. It has been widely accepted that emergence of BK virus correlates with the more potent immunosuppressive agents used to lower acute rejection rates. In contrast to other opportunistic infections after transplantation, for which routine prophylactic agents are administered, there is no effective agent for the prevention of BK infection. Some data, however, suggests that quinolone antibiotics such as ciprofloxacin may have activity against BK virus. This has led us to investigate whether routine, short-term ciprofloxacin administration post-transplant can lower the incidence of BK infection.

Clinical Trial Description

BK virus is a member of the virus family polyomaviridae ("polyoma"). The virus, which can manifest as a viral nephritis, was first described in a renal transplant recipient in 1971, however it was not until the past decade that infection with BK virus became known as an important contributor to graft dysfunction and graft loss after renal transplantation. It has been widely accepted that emergence of BK virus correlates with the more potent immunosuppressive agents currently used to lower acute rejection rates. In contrast to other opportunistic infections after transplantation, for which routine prophylactic agents are administered, there is no effective agent for the prevention of BK infection, nor is there an effective agent for treating BK infection once it occurs.

Ciprofloxacin is a well known anti-infective agent in the fluoroquinolone class of antibiotics. It is most active against gram-negative enteric pathogens, and is commonly used for a variety of infectious indications.

Though classified as antibacterial agents, fluoroquinolones have been suggested to exhibit anti-BK viral effects by interfering with helicase activity of the BK virus large T antigen. Ciprofloxacin has been shown in previous studies to reduce urine BK viral load, and BK-associated hemorrhagic cystitis in the stem cell transplant population. Ciprofloxacin has also been associated with a lower incidence of BK viremia in one retrospective study in kidney transplant recipients. Based on these reports, the investigators hope to find a reduction BK viremia and BK nephropathy using a prospective, randomized study design. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT01789203
Study type	Interventional
Source	The Methodist Hospital System
Contact
Status	Completed
Phase	Phase 4
Start date	January 2013
Completion date	October 2017

View Details

See also
Status	Clinical Trial	Phase
Withdrawn	`NCT02758288` - BK Virus Post-Kidney Transplant: New Practice Versus Traditional Approach
Completed	`NCT01624948` - Safety and Efficacy Study of Everolimus to Treat BK Virus Infection in Kidney Transplant Recipients	Phase 4
Active, not recruiting	`NCT05026021` - Prediction of BKvirus Nephropathy Risk by the NEPHROVIR Method in Kidney Transplant Patients With BKvirus Viremia
Recruiting	`NCT05511779` - Study to Confirm of the Safety and Tolerability of Brincidofovir in Subjects With BK Virus Infection (Viremia) After Kidney Transplantation	Phase 2
Recruiting	`NCT05183490` - R-MVST Cells for Treatment of Viral Infections	Phase 1
Active, not recruiting	`NCT00684372` - BK Viremia After Renal Transplantation	N/A
Recruiting	`NCT06219616` - Prediction of BK Virus Reactivation in Kidney Transplant Recipient	N/A
Not yet recruiting	`NCT05264259` - New Therapeutic Approach Against BK Virus Infection Based on Monoclonal Antibodies
Completed	`NCT04605484` - Study of Posoleucel (Formerly Known as ALVR105; Viralym-M) in Kidney Transplant Patients With BK Viremia	Phase 2
Terminated	`NCT05305040` - Study of Posoleucel (ALVR105,Viralym-M) for Multi-Virus Prevention in Patients Post-Allogeneic Hematopoietic Cell Transplant	Phase 2/Phase 3
Terminated	`NCT04390113` - Study to Evaluate Viralym-M (ALVR105) for the Treatment of Virus-Associated Hemorrhagic Cystitis (HC)	Phase 3
Withdrawn	`NCT02313844` - Most Closely Human Leukocyte Antigen (HLA)-Matched BK Virus-specific T Lymphocytes (Viralym-B)	Phase 1
Active, not recruiting	`NCT03532971` - Prospective Study of BK Virus Disease After Allogeneic Hematopoietic-cell Transplantation: Defining BK Disease's Natural History, Clinical Spectrum, Immunology, and Outcomes
Recruiting	`NCT02479698` - Cytotoxic T Lymphocytes in Treating Patients With Malignancies With BK and/or JC Virus	Phase 2
Recruiting	`NCT05101213` - Study Assessing the Feasibility, Safety and Efficacy of Genetically Engineered Glucocorticoid Receptor Knock Out Virus Specific CTL Lines for Viral Infections in Immunosuppressed Cancer Patients	Phase 1
Completed	`NCT04693637` - Posoleucel (ALVR105, Formerly Viralym-M) for Multi-Virus Prevention in Patients Post-Allogeneic Hematopoietic Cell Transplant	Phase 2/Phase 3
Recruiting	`NCT05618275` - Role of Neutralizing Antibodies in the Prediction and Treatment of BK Virus Infection in Hematopoietic Stem Cell Allograft Patients at the Pediatric Oncology-hematology Department of the HUS
Recruiting	`NCT04542733` - The Efficacy of Everolimus With Reduced-dose Tacrolimus Versus Reduced-dose Tacrolimus in Treatment of BK Virus Infection in Kidney Transplantation Recipient	N/A
Recruiting	`NCT05042076` - BK With VST for Kidney Transplant Patients	Phase 1
Completed	`NCT04294472` - A Safety, Pharmacokinetics and Efficacy Study of MAU868 for the Treatment of BK Viremia in Kidney Transplant Recipients	Phase 2